Effect of four neuraminidase inhibitors on influenza in Osaka, Japan: An eight‐year survey
| Autor: | Naoko Yoshii, Takashi Hamazaki, Yoshihiro Tochino, Tomoya Kawaguchi, Taichi Shuto, Hiroshi Kakeya, Masashi Fujioka |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Oseltamivir
medicine.medical_specialty medicine.drug_class 01 natural sciences 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Zanamivir Internal medicine Pandemic Internal Medicine medicine 030212 general & internal medicine 0101 mathematics Medical prescription fever lcsh:R5-920 biology Neuraminidase inhibitor business.industry questionnaire 010102 general mathematics neuraminidase inhibitor virus diseases Original Articles Laninamivir chemistry biology.protein Peramivir Original Article Geriatrics and Gerontology Family Practice business influenza lcsh:Medicine (General) Neuraminidase medicine.drug |
| Zdroj: | Journal of General and Family Medicine, Vol 21, Iss 1, Pp 18-23 (2020) Journal of General and Family Medicine |
| ISSN: | 2189-7948 |
| Popis: | Background After the A/H1N1 influenza pandemic in 2009, two new drugs against influenza, namely laninamivir and peramivir, were released in 2010 in Japan. We investigated prescription trends of four neuraminidase inhibitors (NAIs), which are laninamivir, peramivir, oseltamivir, and zanamivir, and assessed clinical data related to influenza for 8 years. Methods Patients living in Osaka Prefecture and diagnosed with influenza responded to a postcard questionnaire that collected data regarding their demographic characteristics, symptoms including fever, prescribed drugs, and influenza type. Results Laninamivir was most prescribed to patients aged ≥ 10 years, and oseltamivir was most prescribed to patients aged We showed the data of eight seasons and report prescription trends of four neuraminidase inhibitors (NAIs) and time course of fever in patients after taking these inhibitors. Doctors, especially general physicians, should consider how to choose anti‐influenza drugs. This study based on our 8‐year survey should be helpful to them when deciding which NAIs should be chosen in clinical settings and for which patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text